Ampio Pharmaceuticals Inc. [AMPE] is -71.40% lower this YTD. Is it still time to buy?

Related

Ampio Pharmaceuticals Inc. [AMEX: AMPE] closed the trading session at $0.16 on 07/14/22. The day’s price range saw the stock hit a low of $0.16, while the highest price level was $0.18. The company report on June 2, 2022 that Ampio Pharmaceuticals’ CEO Mike Martino Issues Letter to Stockholders.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, today released the following letter to stockholders from its Chief Executive Officer, Mike Martino.

The stocks have a year to date performance of -71.40 percent and weekly performance of -3.15 percent. The stock has been moved at -70.01 percent over the last six months. The stock has performed -26.71 percent around the most recent 30 days and changed -58.83 percent over the most recent 3-months.

If compared to the average trading volume of 4.69M shares, AMPE reached to a volume of 2219870 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Ampio Pharmaceuticals Inc. [AMPE]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AMPE shares is $2.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AMPE stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

ROTH Capital have made an estimate for Ampio Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 19, 2019. While these analysts kept the previous recommendation, Aegis Capital raised their target price from $15 to $16. The new note on the price target was released on March 17, 2014, representing the official price target for Ampio Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $11, while Aegis Capital analysts kept a Buy rating on AMPE stock.

The Average True Range (ATR) for Ampio Pharmaceuticals Inc. is set at 0.02 The Price to Book ratio for the last quarter was 1.63, with the Price to Cash per share for the same quarter was set at 0.14.

AMPE stock trade performance evaluation

Ampio Pharmaceuticals Inc. [AMPE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.15. With this latest performance, AMPE shares dropped by -26.71% in over the last four-week period, additionally sinking by -70.01% over the last 6 months – not to mention a drop of -89.13% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AMPE stock in for the last two-week period is set at 44.04, with the RSI for the last a single of trading hit 43.59, and the three-weeks RSI is set at 43.39 for Ampio Pharmaceuticals Inc. [AMPE]. The present Moving Average for the last 50 days of trading for this stock 0.1904, while it was recorded at 0.1709 for the last single week of trading, and 0.6580 for the last 200 days.

Ampio Pharmaceuticals Inc. [AMPE]: An insightful look at the core fundamentals

Return on Equity for this stock declined to -76.23, with Return on Assets sitting at -55.35.

Ampio Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.40 and a Current Ratio set at 5.40.

Ampio Pharmaceuticals Inc. [AMPE]: Insider Ownership positions

There are presently around $8 million, or 21.90% of AMPE stock, in the hands of institutional investors. The top three institutional holders of AMPE stocks are: BLACKROCK INC. with ownership of 13,996,074, which is approximately 0.44% of the company’s market cap and around 7.64% of the total institutional ownership; VANGUARD GROUP INC, holding 9,307,338 shares of the stock with an approximate value of $1.54 million in AMPE stocks shares; and STATE STREET CORP, currently with $0.57 million in AMPE stock with ownership of nearly 1.973% of the company’s market capitalization.

Positions in Ampio Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 33 institutional holders increased their position in Ampio Pharmaceuticals Inc. [AMEX:AMPE] by around 2,783,295 shares. Additionally, 43 investors decreased positions by around 12,847,297 shares, while 65 investors held positions by with 33,404,024 shares. The mentioned changes placed institutional holdings at 49,034,616 shares, according to the latest SEC report filing. AMPE stock had 11 new institutional investments in for a total of 2,259,375 shares, while 11 institutional investors sold positions of 10,019,303 shares during the same period.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]